N-[(2-chloro-6-methylphenyl)carbonyl]-4-(5-chloro-1-methyl-2-oxo-3-pyridinyl)-L-phenylalanine | 343981-06-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[(2-chloro-6-methylphenyl)carbonyl]-4-(5-chloro-1-methyl-2-oxo-3-pyridinyl)-L-phenylalanine
• 英文别名: (2S)-2-[(2-chloro-6-methylbenzoyl)amino]-3-[4-(5-chloro-1-methyl-2-oxopyridin-3-yl)phenyl]propanoic acid
• CAS: 343981-06-6
• 化学式: C₂₃H₂₀Cl₂N₂O₄
• 分子量: 459.329
• InChiKey: IMOMSSUKSKNQTH-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  86.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-[(2-chloro-6-methylphenyl)carbonyl]-4-(5-chloro-1-methyl-2-oxo-3-pyridinyl)-L-phenylalanine methyl ester 在 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 以82%的产率得到N-[(2-chloro-6-methylphenyl)carbonyl]-4-(5-chloro-1-methyl-2-oxo-3-pyridinyl)-L-phenylalanine
  参考文献：
  名称：

  4-pyridinyl-n-acyl-l-phenylalanines

  摘要：

  式I化合物具有作为VCAM-1与表达VLA-4的细胞之间结合抑制剂的活性，并且适用于治疗症状和/或损害与VCAM-1与表达VLA-4的细胞结合相关的疾病。

  公开号：

  US06388084B1

文献信息

• 4-Pyridinyl-n-acyl-l-phenylalanines
  申请人：——

  公开号：US20040127706A1

  公开（公告）日：2004-07-01

  Compounds of Formula I have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4 and are useful for treating disease whose symptoms and or damage are related to the binding of VCAM-1 to cells expressing VLA-4.

  公式I的化合物具有抑制VCAM-1与表达VLA-4的细胞之间结合的活性，并且可用于治疗与VCAM-1与表达VLA-4的细胞之间结合有关的症状和/或损伤的疾病。
• 4-pyridinyl-N-acyl-L-phenylalanines
  申请人：——

  公开号：US20020133015A1

  公开（公告）日：2002-09-19

  Compounds of Formula I have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4 and are useful for treating disease whose symptoms and or damage are related to the binding of VCAM-1 to cells expressing VLA-4.

  化合物I的活性是抑制VCAM-1与表达VLA-4的细胞之间的结合，并且可用于治疗症状和/或损伤与VCAM-1与表达VLA-4的细胞之间的结合有关的疾病。
• 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1244625B1

  公开（公告）日：2005-06-15
• Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
  申请人：Lieberburg Ivan

  公开号：US20080044382A1

  公开（公告）日：2008-02-21

  Alpha 4 inhibitors are used in treatment of inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, rheumatoid arthritis and asthma. Rare occurrences of progressive multifocal leucoencephalopathy during treatment with an alpha-4 agent suggest the possibility that it may be related to such treatment. Monitoring for the JC virus and educating caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of alpha 4 inhibitor therapy.
• METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4 INHIBITORY COMPOUNDS
  申请人：Elan Pharmaceuticals, Inc.

  公开号：US20140051655A1

  公开（公告）日：2014-02-20

  Alpha 4 inhibitors are used in treatment of inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, rheumatoid arthritis and asthma. Rare occurrences of progressive multifocal leucoencephalopathy during treatment with an alpha-4 agent suggest the possibility that it may be related to such treatment. Monitoring for the JC virus and educating caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of alpha 4 inhibitor therapy.